Abstract
We recently identified fingolimod as a potent antibiofilm compound by screening FDA-approved drugs. To study if the antibacterial activity of fingolimod could be further improved and to explore in-depth structure-activity relationships, we synthesized 28 novel fingolimod derivatives and evaluated their efficacy against Staphylococcus aureus grown in planktonic/single cell and biofilms. The most effective derivatives were tested on preformed S. aureus biofilms and against Gram-negative bacteria Acinetobacter baumannii and Pseudomonas aeruginosa, using fingolimod as the reference compound. Seven derivatives were more effective against S. aureus, while five other derivatives showed improved activity against P. aeruginosa and/or A. baumannii, with no apparent change in cytotoxicity on human cells. The most interesting derivatives, compounds 43 and 55, displayed a broader spectrum of antibacterial activity, possibly exerted by the change of the para-hydrocarbon chain to a meta position for 43 and by an additional hydroxyl group for 55.
Original language | English |
---|---|
Journal | ACS Omega |
Volume | 6 |
Issue number | 28 |
Pages (from-to) | 18465-18486 |
Number of pages | 22 |
ISSN | 2470-1343 |
DOIs | |
Publication status | Published - 9 Jul 2021 |
MoE publication type | A1 Journal article-refereed |
Fields of Science
- 317 Pharmacy
- BIOFILM
- SUSCEPTIBILITY
- SPHINGOSINE
- PATHOGENESIS
- DISCOVERY
- DESIGN
- BASES
Equipment
-
Viikki Metabolomics Unit (LS-RIA/ Metabo-HiLIFE)
Sipari, N. (Manager)
Faculty of Biological and Environmental SciencesFacility/equipment: Core Facility